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Background. Irritable bowel syndrome (IBS) is a chronic, diﬃcult to treat condition. The eﬃcacy of Aloe vera in treating IBS
symptoms is not yet proven. The purpose of this study was to determine if Aloe vera is eﬀective in improving quality of life.
Methods. A multicentre, randomised, double-blind, cross-over placebo controlled study design. Patients were randomised to Aloe
vera, wash-out, placebo or placebo, washout, Aloe vera. Each preparation (60mL) was taken orally twice a day. Patient quality of
life was measured using the Gastrointestinal Symptoms Rating Score, Irritable Bowel Syndrome Quality of Life, EuroQol and the
Short-Form-12 at baseline and treatment periods 1 and 2. Results. A total of 110 patients were randomised, but only 47 completed
all questionnaires and both study arms. Statistical analysis showed no diﬀerence between the placebo and Aloe vera treatment in
quality of life. Discussion. This study was unable to show that Aloe vera was superior to placebo in improving quality of life. Drop
outs and other confounding factors may have impacted on the power of the study to detect a clinically important diﬀerence. Con-
clusion.ThisstudyfailedtoﬁndAloe vera superiortoplaceboinimprovingqualityoflifeprovenIrritableBowelSyndromepatients.
1.Introduction
Irritablebowelsyndrome(IBS)isafunctionalboweldisorder
in which abdominal discomfort or pain is associated with
a change in bowel habit, and with features of disordered
defecation [1]. Some suﬀerers may have coexisting anxiety
or depression [2, 3].
Community-based studies have highlighted that persons
with IBS have greater disability and a threefold higher absen-
teeism from work than do healthy controls leading to greater
health care utilisation [4–7]. It has been suggested that
psychosocial distress in IBS patients inﬂuences health-care
seeking behaviour [8–10]. Patients with IBS also have poorer
quality of life than persons without the disorder [4–6].
Surveys of Western populations have revealed preva-
lences of IBS between 15–20% with a higher prevalence in
women [8]. However, despite its prevalence, there remains
ap r o v e nl a c ko fs a f ee ﬃcacious medical treatments for
IBS [11]. Conventional treatments include antispasmodics,
antidiarrheals, antidepressants, and anxiolytics medications
[1, 2, 12, 13]. A review of randomized, controlled trials
found no convincing evidence to support the eﬃcacy of any
medication but highlighted ﬂaws in the methodology of the
trials [14] .Am o r er e c e n tr e vi e wf o u n dt h a ts o m et r e a t m e n t s
were beneﬁcial for individual symptoms but highlighted the
factthattreatmentshouldbetargetedatthemajorsymptoms
[13]. No single treatment appears to be eﬀective in relieving
all the symptoms associated with the disorder.2 ISRN Gastroenterology
Growing numbers of patients have turned to comple-
mentary and alternative medicine (CAM) after failing to ﬁnd
adequate relief from conventional remedies [15, 16]. It has
previously been reported that usage of alternative treatments
wasgreaterforIBSthansomeothergastrointestinaldisorders
and that up to 41% of IBS patients would consult an
alternative practitioner if conventional remedies failed [17,
18]. Alternative treatments for IBS include hypnosis [11, 19],
acupuncture [15], cognitive behaviour therapy [20], yoga
[2], and herbal remedies (such a peppermint oil [21]a n d
Chinese herbal medicines [22]) which have been associated
with varying degrees of success.
The Aloe vera plant is a perennial succulent with thick
leaves whose central pulp consists of large, thin-walled cells
containing a thin clear jelly-like Aloe vera gel [23]. There
has been a growing commercial interest in Aloe vera gel,
which is used both topically in cosmetic products and herbal
remediesanddrinks[24].ExternallyAloe productshavebeen
used for treatment of wounds, burns, and skin irritations.
Aloe Vera drinks have been promoted for constipation,
coughs, wounds, ulcers, diabetes, cancer, headaches, and
many other [23, 25]. Although there is evidence of eﬃcacy
of Aloe vera in some conditions, there is limited data
available for most conditions [25]. Aloe is commonly used
in IBS, particularly the constipation-predominant subtype
[26].
Although it is considered “safe” there are currently lim-
ited data regarding the eﬃcacy of Aloe vera in the treatment
of IBS. A study assessing a compound containing celandine,
Aloe vera and psyllium in the treatment of constipation
resulted in an greater symptom improvement in the active
group when compared to placebo [27]. There have been no
large randomised controlled studies assessing the action of
Aloe vera alone in a cross-over fashion. The purpose of this
study was therefore to assess the eﬃcacy of an Aloe vera gel
drink compared with a placebo in patients with recognised
IBS.
2. Methods
2.1. Study Design. The study was a multi-centre prospective
randomised, placebo-controlled, double-blind, cross-over
study. The study took place in three hospitals in South
West Wales, UK. Following screening, patients were ran-
domly allocated into one of two groups. Following baseline
assessments patients entered a two-week screening period
followed by a ﬁve-month treatment period (part 1). At the
end of this period there was a two week wash-out period.
Patients then entered a second ﬁve-month treatment period
when they received the alternative treatment (part 2). Group
AB consisted of an Aloe vera drink 60mls twice daily for
ﬁve months followed by two weeks wash out then matched
placebo drink for 60mls twice daily for ﬁve months. Group
BA consisted of placebo for ﬁve months, two week washout,
then Aloe vera for ﬁve months. Both Aloe vera and placebo
drinks were identical in taste and produced by the same
manufacturer. The study was approved by the Local Research
Ethics Committee.
2.2. Patient Selection. Inclusion criteria were male or female
patients aged at least 18 years, diagnosed as suﬀering with
Irritable Bowel Syndrome (IBS) according to the Rome
II criteria [1] for at least one year and had received
previous treatment; were complaining of abdominal pain;
were seeking further treatment; were able and willing to give
consent to be randomised into the study. Female patients
were included if they were taking adequate contraceptive
precautions and had a negative pregnancy test at baseline.
Patients on medication for stable medical conditions not
considered to exert an eﬀect on the study intervention were
eligible for recruitment. Certain medications for relief of
diarrhoea or constipation were permitted. Patients were
excluded if they had signiﬁcant other GI tract disease, had
u n d e r g o n ep r e v i o u sG It r a c ts u r g e r y ,w e r ek n o w nt ob e
defaulters at clinic and might be diﬃcult to follow up, were
on drugs which might aﬀect motility, or had a current or
recent history of drug or alcohol abuse.
2.3. Study Evaluation and Statistical Tests. The primary
outcome measure was patient quality of life. Four quality
of life scales were used in the study completed by patients
at baseline, end of study period 1 (5 months) and end of
study period 2 (10 months). Compliance with treatment
was assessed by measuring the number of returned empty
containers at the end of each study period.
2.3.1. Gastrointestinal Symptoms Rating Scale (GSRS) [28,
29]. This is a disease-speciﬁc quality of life questionnaire.
The scoring system originally devised for measuring changes
in psychopathology, has been modiﬁed for use in patients
with IBS and peptic ulcer disease. The GSRS scoring system
has been evaluated in the UK and Scandinavia. Four
subscales (abdominal pain syndrome, dyspeptic syndrome,
indigestion syndrome, bowel dysfunction syndrome) and a
total gastrointestinal symptoms score were calculated from
the GSRS.
2.3.2. EuroQol (EQ5D) Questionnaire [30, 31]. E Q - 5 Di sa
generic instrument for use as a measure of health outcome.
Applicable to a wide range of health conditions and treat-
ments, it provides a simple descriptive proﬁle and a single
index value for health status. EuroQol assessment consisted
of a descriptive score based on 5 health dimensions together
with a self-rated visual analogue score.
2.3.3. Short Form 12 (SF 12) Quality of Life Questionnaire
[32]. This is a shortened version of the generic SF36 ques-
tionnaire [33]. It has been well validated and is considered
to be almost as eﬃcient as the full version for assessing
patients’ quality of life [32, 34]. Two summary scores were
calculated from the SF-12, a Physical Component Summary
Scale Score (PCS), and a Mental Component Summary Scale
Score (MCS).
2.3.4. The Irritable Bowel Syndrome Quality of Life Question-
naire (IBSQOL) [35, 36]. This is a disease-speciﬁc quality of
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The IBSQOL questionnaire produced 8 subscales scores for
each patient: emotional health, mental health, sleep, energy,
physical functioning, diet, social role, and physical role.
2.4. Statistical Analysis. Independent sample t-tests or Chi-
square tests were used prior to any treatment at baseline
to check that the two treatment groups were comparable.
Data for patients who were randomised into a group and
then failed to continue after visit two were assessed on
an intention to treat basis, that is, within their original
treatment allocation group. Statistical analysis was carried
out to diﬀerentiate any genuine treatment eﬀects from
possible “carry-over” eﬀects introduced by the diﬀerent
order in which the patients received the study treatment.
Data were analysed according to statistical procedures for
full cross-over trials as recommended by Armitage and Berry
[37] when there was no strong carry-over eﬀect. Cross-over
comparisons were based on those subjects with data for the
end of treatment period one and the end of treatment period
two (i.e., at 5 months and 10 months).
2.4.1. Power of the Study. When analysed as a full crossover
study, a sample size of 55 per group would have an 80%
power to detect a diﬀerence of 0.37 SD (12 points in patient
quality of life scores) at a signiﬁcance of 0.05. If necessary,
when analysed as a simple randomised trial, a sample size of
55 per group would have an 80% power to detect a diﬀerence
of 0.54 SD (16 points in patient quality of life scores) at a
signiﬁcance of 0.05.
3. Results
During the period from 1st August 2001 to 31st July 2003 a
total of 1080 patients notes/clinic letters from three hospitals
in South West Wales, UK (Morriston Hospital, Singleton
Hospital and Neath Hospital) were screened to identify suit-
able patients. A further 120 patients were screened following
self-referral via responses to posters in GP practices. Letters
were sent to 414 of these patients inviting them to discuss the
study. A total of 124 patients consented to enter the study of
which 110 were randomised. Figure 1 shows a ﬂow diagram
of the patient recruitment in the study.
Baseline analysis of the data highlighted that the two
groups were well matched and that there were no signiﬁcant
diﬀerences between the two groups with respect to their
demography or symptoms (Table 1).
3.1. Comparison of Quality of Life Scores. When taking into
account the ordering of the treatments, there were found to
be no signiﬁcant diﬀerences between any of the scores for the
generic or disease-speciﬁc scales based on the ordering that
the treatments were received (P>. 05 for all comparisons).
Similarly there were found to be no treatment period eﬀects
for any of the scores on the generic or disease-speciﬁc scales
(P>. 05 for all comparisons).
Astherewerenosigniﬁcant orderingortreatmentperiod
eﬀects, the results for each scale were analysed as a full
cross-over study. The cross-over analysis identiﬁed that there
were no signiﬁcant diﬀerences between treatment A and B
with respect to the generic SF-12 or EQ-5D scores (P>
.05 for all comparisons). Similarly, no signiﬁcant diﬀerences
were found between treatment A and B with respect to the
disease speciﬁc scores generated from the GSRS and IBSQOL
(P>. 05 for all comparisons). Figures 2 and 3 illustrate the
mean scores for the GSRS (dyspeptic syndrome, indigestion
syndrome, bowel dysfunction, and total GSRS score) and
IBSQOL (emotional health, mental health, sleep, energy,
physical function, diet, social role and physical role) for each
treatment period.
3.2. Compliance. Both study groups were fully compliant
with the assigned treatments with all treatment containers
being returned empty.
4. Discussion
This study failed to ﬁnd Aloe vera superior to placebo in
improving any aspect of patient quality of life using either
disease speciﬁc or generic quality of life measures in this
group of patients with proven Irritable Bowel Syndrome
(IBS) (according to the Rome II Criteria [1]). Compliance
with treatment in those who entered and or completed both
armsofthestudyappearedtobeacceptableasdeterminedby
the number of returned empty containers.
Poor recruitment numbers, a large number of patients
withdrawing from the study and the long treatment period
all may have had an eﬀect on the results. In addition,
although over 1000 patients were initially identiﬁed with
symptoms suggestive of IBS only about 10% of these were
recruited, which could mean that our sample was not truly
representative of the broad spectrum of IBS patients. All
patients who entered the study did however meet the Rome
II criteria [1] for IBS so were considered appropriate.
The need for patients to discontinue certain medications
prior to entry into the study was unacceptable to some
patients and again impacted on recruitment. The reduced
recruitment rate aﬀected the power of the study and
was further compounded by the number of patients who
discontinued throughout the study for a variety of reasons
which included an increase in symptoms in both groups
but more marked in the Aloe vera arm of the study. The
ﬁnal sample was only suﬃcient to detect relatively large
diﬀerences in quality of life scores between the two groups. A
larger sample with fewer drop outs may have detected some
diﬀerence between the two groups. Our results mirror those
reported in a small study of patients with ulcerative colitis
which was unable to detect any diﬀerences in quality of life
scores following Aloe vera treatment [38].
Although a great deal of time was spent recruiting and
discussing the study with patients this did not prevent
a large number of nonattendances at randomisation and
throughout the study. Attempts by mail and telephone did
not elicit a response from some patients. The long duration
of the study and the completion of a comprehensive daily
diary card throughout the study may have resulted in the loss
of some patients. The visits were fairly well spaced out and4 ISRN Gastroenterology
Assessed for eligibility (n = 1200)
Notes/clinic letters (n = 1080)
Self-referrals (n = 120)
Suitable for study (n = 414)
Consented (n = 124)
Randomized (n = 110)
Allocated Aloe vera/placebo (n = 55)
Lost to follow-up
SF-12 (n = 33)
EuroQol (n = 36)
GSRS (n = 34)
IBSQOL (n = 27)
Completed treatment
SF-12 (n = 22)
EuroQol (n = 19)
GSRS (n = 21)
IBSQOL (n = 28)
Allocated placebo/Aloe vera (n = 55)
248 declined
35 did not attend screening
visits
5 further investigation
required
2 coeliac disease
Randomization visit
10 did not attend screening
visits
2 declined
2 coeliac disease
Lost to follow-up
SF-12 (n = 29)
EuroQol (n = 27)
GSRS (n = 26)
IBSQOL (n = 22)
Completed treatment
SF-12 (n = 26)
EuroQol (n = 28)
GSRS (n = 29)
IBSQOL (n = 33)
Figure 1: Patient progress through the stages of the trial.
there was some ﬂexibility in attendance days and time of day
so we do not consider actual attendance would have had a
great impact on preventing patients taking part in the study.
IBS is a functional gastrointestinal condition that has
many components, which make it diﬃcult to assess and
treat [11, 39]. IBS can be associated with many symptoms
including diarrhoea, constipation, abdominal pain, nausea,
bloating, unsatisfactory defaecation, and exhaustion, with
patients suﬀering some or all at diﬀerent times. This mixed
symptomatology makes treatment diﬃcult with orthodox
medicine[40].Variousapproacheshavebeenadoptedforthe
treatmentofIBSrangingfromdrugstodietarymodiﬁcations
and counselling. The complex nature of IBS may mean that
certain subpopulations of patients with IBS could beneﬁt
from Aloe vera.I ns o m es u ﬀerers there is considered to be a
substantial emotional and psychological component to IBS
again making compliance diﬃcult. It may be that patients
whose symptoms are more physical have a better response in
respectofqualityoflife.However,duetoourreducedsample
size, our study was not suﬃciently robust to detect this or to
fully determine which subpopulations of IBS might beneﬁt.
Thedisorderisalsocharacterisedbyspontaneousrelapseand
remission and there is a recognised strong placebo response
to treatment [14]. Both the Aloe vera and placebo arms
showed improvements in some quality of life scores during
the treatment periods although the diﬀerences were not
sustained or signiﬁcant. The placebo response to symptoms
ofirritablebowelsyndromehasbeenpreviouslydocumented
and the duration and degree of this eﬀect may have had
an impact on our ability to separate the two treatments
[39, 41, 42]. It may also be that the individuals recruited
to the study are strongly in favour of alternative medicines
with a strong belief in the therapies and a commitment to
the concept that they will work [43, 44]. In these individuals
t h ep l a c e b or e s p o n s ei sl i k e l yt ob ee v e nm o r ee x a g g e r a t e d .
The study used a cross-over design with patients being
their own control in an attempt to try and reduce some of
these eﬀects. This design in itself was associated with prob-
lems, predominantly large numbers of drop outs. Although
we feel that a cross-over study was the most appropriate
design, the requirement for a long study duration and the
associated problems of patient retention especially for a
disorder as complex as IBS limits its potential. A more
conventional parallel group design may have been more
useful in terms of retaining patients. The statistical analysis
was undertaken on patients who completed both sequences
and this resulted in a further loss of subjects. An assessment
of generic and disease-speciﬁc quality of life questionnaires
showed no signiﬁcant diﬀerence between the Aloe vera and
placebo group with respect to improvement of symptoms.ISRN Gastroenterology 5
Table 1: Baseline characteristics of the study population by randomisation group.
Description Group
Aloe vera/Placebo Placebo/Aloe vera P-value
Number 55 55
Sex(F:M) 42:13 42:13 >.05
Mean age (SD) yr 46.0 (13.6) 47.0 (13.7) >.05
Mean weight (SD) kg 73.1 (17.4) 74.5 (16.6) >.05
Mean height (SD) cm 164.4 (9.4) 165.4 (10.3) >.05
Smokers, n (%) 10 (18) 14 (26) >.05
AlcoholY:N 36:19 34:21 >.05
Employed, n (%) 32 (58) 26 (47) >.05
Main IBS symptom, n (%)
Pain 19 (35) 25 (46) >.05
Bloating 6 (11) 10 (18) >.05
Constipation 7 (13) 3 (6) >.05
Diarrhoea 14 (26) 12 (22) >.05
Alternating diarrhoea/ 9 (16) 5 (9) >.05
constipation
Approx length of symptoms >.05
per episode, n (%)
0–3 days 18 (33) 16 (29)
4–7 days 9 (16) 8 (15)
>7 days 28 (51) 31 (56)
Approx length of time >.05
between episodes, n (%)
<2 weeks 48 (87) 42 (76)
2–4 weeks 5 (9) 9 (16)
>1m o n t h 2( 4 ) 4( 8 )
Fibre intake, n (%) >.05
Low 13 (24) 12 (22)
Medium 24 (44) 26 (47)
High 17 (32) 17 (31)
Mean systolic blood 132.2 (18.8) 132.5 (17.8) >.05
pressure (range) mmHg
Mean diastolic blood 83.2 (13.1) 81.5 (11.0) >.05
pressure (range) mmHg
Mean heart rate (range) 71.9 (10.8) 74.1 (10.0) >.05
bpm6 ISRN Gastroenterology
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Dyspeptic syndrome group AB
Dyspeptic syndrome group BA
Indigestion syndrome group AB
Indigestion syndrome group BA
Bowel dysfunction group AB
Bowel dysfunction group BA
Total GSRS score group AB
Total GSRS score group BA
Figure 2: Gastrointestinal Symptoms Rating Scale Questionnaire
(GSRS) Dyspeptic syndrome, Indigestion syndrome, Bowel dys-
function and Total scores for each study group at baseline, period
1( 5m o n t h s )a n dp e r i o d2( 1 0m o n t h s ) .
Caution must be used when interpreting these ﬁndings as
the total patient numbers are small and the ﬂuctuating
nature of the disorder could also aﬀect the results. The
treatment periods themselves were of fairly short duration
for a disorder of this nature and it could be that a
longer treatment period would counteract some of these
eﬀects. Other authors have documented that management
of IBS requires long term involvement of the patient as no
single treatment has been shown to be predictably eﬀective
[45].
At the time of the study we were not aware that some
patients might experience increased symptoms on commen-
cing Aloe vera, and in practice the dose is titrated down and
then up again which from discussion with the manufacturer
of the Aloe vera often resolves the issue. Unfortunately as the
duration of each arm of the study was only ﬁve months this
was not considered appropriate but in hindsight might have
prevented some of the withdrawals.
It has been noted that the severity of patient symptoms
and their eﬀects on patient quality of life should guide treat-
ment and that a comprehensive and multifaceted approach
to treatment is required [12].
Thisstudyhasthereforefailedtodemonstrateanybeneﬁt
for Aloe vera in IBS, but it has also highlighted the diﬃculty
ofrandomisedtrialsinthiscondition.Wewouldrecommend
further studies addressing some of the shortfalls of the
current study including a more ﬂexible treatment approach,
longer treatment duration, and larger sample size.
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Emotional health group AB
Emotional health group BA
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Sleep group BA
Energy group AB
Energy group BA
Physical function group AB
Physical function group BA
Diet group AB
Diet group BA
Social role group AB
Social role group BA
Physical role group AB
Physical role group BA
Figure 3: The Irritable Bowel Syndrome Quality of Life question-
naire (IBSQOL) Emotional health, Mental health, Sleep, Physical
f u n c t i o n ,D i e t ,S o c i a lr o l ea n dP h y s i c a lr o l es c o r e sf o re a c hs t u d y
group at baseline, period 1 (5 months) and period 2 (10 months).
5. Conclusions
This study failed to ﬁnd Aloe vera superior to placebo in
improving patient assessed quality of life (using two generic
and two disease-speciﬁc quality of life tools) in a group of
patients with proven Irritable Bowel Syndrome (according to
the Rome II Criteria [1]).
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